Investors can speculate about the future of a stock by watching how its insiders buy and sell stocks. Vertex Pharmaceuticals, Inc shares valued at $102,860 were purchased by Bhatia Sangeeta N. on Aug 27 ’25. At $386.69 per share, Bhatia Sangeeta N. acquired 266 shares.
Also, Kewalramani Reshma purchased 10,000 shares, netting a total of over 3,895,768 in proceeds. Following the buying of shares at $389.58 each, the insider now holds 115,968 shares.
Before that, SACHS BRUCE I had added 5,000 shares to its account. In a trade valued at $1,948,416, the Director bought Vertex Pharmaceuticals, Inc shares for $389.68 each. Upon closing the transaction, the insider’s holdings increased to 5,000 shares, worth approximately $17.51 million.
As published in a research note from Wells Fargo on August 06, 2025, Vertex Pharmaceuticals, Inc [VRTX] has been rated up from an Equal weight to an Overweight and the price target has been revised to $460. Analysts at Wolfe Research downgraded the stock from ‘”an Outperform”‘ to ‘”a Peer perform”‘ outlook in a report released in early May. As of May 06, 2025, Leerink Partners has decreased its “an Outperform” rating to a “Market perform” for VRTX.
Analyzing VRTX Stock Performance
On last trading session, Vertex Pharmaceuticals, Inc [NASDAQ: VRTX] rose 0.49% to $389.08. The stock’s lowest price that day was $385.99, but it reached a high of $390.37 in the same session. During the last five days, there has been a drop of approximately -1.34%. Over the course of the year, Vertex Pharmaceuticals, Inc shares have dropped approximately -19.15%. Shares of the company reached a 52-week high of $519.68 on 03/14/25 and a 52-week low of $362.50 on 08/11/25.
Support And Resistance Levels for Vertex Pharmaceuticals, Inc (VRTX)
According to the 24-hour chart, there is a support level at 386.59, which, if violated, would cause prices to drop to 384.10. In the upper region, resistance lies at 390.97. The next price resistance is at 392.86. RSI (Relative Strength Index) is 38.80 on the 14-day chart, showing neutral technical sentiment.
Is Vertex Pharmaceuticals, Inc subject to short interest?
Stocks of Vertex Pharmaceuticals, Inc saw a sharp steep in short interest on 2025-08-15 dropping by -0.49 million shares to 3.7 million. Data from Yahoo Finance shows that the short interest on 2025-07-15 was 4.19 million shares. A decline of -13.17% in short interest reflects a positive sentiment towards the stock. Despite the fact that short shares comprise just 1.72 of the overall float, the days-to-cover ratio (short ratio) decline to 1.72.
Which companies own the most shares of Vertex Pharmaceuticals, Inc (VRTX)?
In terms of Vertex Pharmaceuticals, Inc share price expectations, FactSet research, analysts set an average price target of 478 in the next 12 months, up nearly 23.46% from the previous closing price of $387.18. Analysts anticipate Vertex Pharmaceuticals, Inc stock to reach 553 by 2025, with the lowest price target being 420. In spite of this, 16 analysts ranked Vertex Pharmaceuticals, Inc stock as Buy at the end of 2025. On February 12, 2025, Canaccord Genuity assigned a price target of “a Hold” to the stock and upgraded coverage with a $424.
